Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SWS Hemodialysis Care CoSHSE:688410 +0.38%88 Return-on-Tangible-Equity is 12.91% as of Mar. 2026, which is 131% above its 10-year median of 5.60. GuruFocus rates SHSE:688410 with a GF Score™ of 88/100 and a GF Value™ of ¥15.44 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 758 Medical Devices & Instruments companies, SWS Hemodialysis Care Co ranks better than 66.09% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SWS Hemodialysis Care Co's annualized net income for the quarter that ended in Mar. 2026 was ¥217.9 Mil. SWS Hemodialysis Care Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥1,687.3 Mil. Therefore, SWS Hemodialysis Care Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 12.91%.
The historical rank and industry rank for SWS Hemodialysis Care Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688410'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -25.24 Med: 5.6 Max: 12.7
Current: 9.9
During the past 12 years, SWS Hemodialysis Care Co's highest Return-on-Tangible-Equity was 12.70%. The lowest was -25.24%. And the median was 5.60%.
SHSE:688410's Return-on-Tangible-Equity is ranked better than 66.09% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs SHSE:688410: 9.90
SWS Hemodialysis Care Co (SHSE:688410) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SWS Hemodialysis Care Co Return-on-Tangible-Equity Related Terms
SWS Hemodialysis Care Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SWS Hemodialysis Care Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SWS Hemodialysis Care Co Return-on-Tangible-Equity Chart
SHSE:688410 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, SWS Hemodialysis Care Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SWS Hemodialysis Care Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SWS Hemodialysis Care Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SWS Hemodialysis Care Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.91% mean?
SWS Hemodialysis Care Co (SHSE:688410) has a Return-on-Tangible-Equity of 12.91% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SWS Hemodialysis Care Co and its competitors. This is 131% above median its historical median of 5.60. According to the industry distribution chart, SWS Hemodialysis Care Co ranks #257 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is SWS Hemodialysis Care Co's Return-on-Tangible-Equity too high?
SWS Hemodialysis Care Co's current Return-on-Tangible-Equity of 12.91% is 131% above median its 10-year median of 5.60. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. SWS Hemodialysis Care Co's value of 12.91% is 218.4% above this industry median. Based on the distribution chart, SWS Hemodialysis Care Co ranks #257 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SWS Hemodialysis Care Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SWS Hemodialysis Care Co's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SWS Hemodialysis Care Co ranks #257 out of 758 companies for Return-on-Tangible-Equity. This puts SWS Hemodialysis Care Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.06. SWS Hemodialysis Care Co's value of 12.91% is 218.4% above this benchmark. While the company's 10-year median is 5.60 vs. the industry median of 4.06, SWS Hemodialysis Care Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SWS Hemodialysis Care Co's current Return-on-Tangible-Equity of 12.91% is 218.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SWS Hemodialysis Care Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SWS Hemodialysis Care Co's current Return-on-Tangible-Equity is 12.91%, which is 131% above median its own 10-year median of 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SWS Hemodialysis Care Co stock overvalued right now?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co (SHSE:688410) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.44, compared to a current price of ¥10.59 — trading 31.4% below its estimated fair value. The current Return-on-Tangible-Equity is 12.91%, which is 131% above median its 10-year median of 5.60 and 218.4% above the Medical Devices & Instruments industry median of 4.06. SWS Hemodialysis Care Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SWS Hemodialysis Care Co (SHSE:688410), the current Return-on-Tangible-Equity is 12.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SWS Hemodialysis Care Co (SHSE:688410) Overvalued in 2026?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co stock appears to be undervalued.
The current stock price of ¥10.59 is trading 31.4% below its estimated GF Value™ of ¥15.44.
GuruFocus considers SWS Hemodialysis Care Co to be Significantly Undervalued.
Key valuation signals for SHSE:688410:
Return-on-Tangible-Equity: 12.91% (131% above median its 10-year median of 5.60)
GF Value™: ¥15.44 vs. price of ¥10.59 (31.4% below fair value)
Industry Position: 218.4% above the Medical Devices & Instruments median (#257 of 758)
No single metric tells the full story. See the SHSE:688410 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SWS Hemodialysis Care Co Ltd along with its subsidiaries is engaged in the field of blood purification. Its focused on patients welfare and ensuring the delivery of safe and effective products and services. The group operates through four segments: Blood Purification Equipment, Blood Purification Consumables, advanced Hemodialysis Management System, and Chain Dialysis centers. The organization is delivering medical solutions for patients with chronic kidney disease (CKD). Its products include Blood Purification Equipment Dialysis, Disposables Dialysis Center, Intelligent Management System, and Chain Dialysis centers. SWS is committed to enhancing patient wellness by prioritizing care through advanced integrated blood purification technologies.
88GF Score
Get the complete analysis for SHSE:688410
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688410 has been successfully added to your 
